Adicet Bio to Present at the Cantor Virtual Global Healthcare Conference
Adicet Bio (Nasdaq: ACET) announced that CEO Chen Schor will present at the Cantor Virtual Global Healthcare Conference on September 16, 2020, at 8:40 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adicet Bio (Nasdaq: ACET) announced that CEO Chen Schor will present at the Cantor Virtual Global Healthcare Conference on September 16, 2020, at 8:40 AM ET. A live audio webcast will be available on the company’s website, with a replay accessible for 30 days post-event.
The company specializes in developing allogeneic gamma delta T cell therapies for cancer and other diseases, enhancing immune responses with engineered T cells for better tumor targeting.
Details
News Market Reaction – ACET
The recorded move for ACET in the trading session of this news was -3.51%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer of Adicet Bio, will present at the Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020 at 8:40 AM ET.
A live audio webcast of the presentation can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com. An archived replay will be available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.
Adicet Bio., Inc.
Investor and Media Contacts:
Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.